This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tcelna
™, a novel T-cell therapy for multiple sclerosis (MS), today announced that Neil Warma, President and Chief Executive Officer, will participate in two upcoming industry conferences. Details regarding these events are as follows:
Intellectual Property Owners Association (IPO) Annual Meeting
This conference will take place September 9-11, 2012 at the JW Marriott Hill Country in San Antonio, Texas.
Keynote Luncheon Address
Delivered by Mr. Warma
Tuesday, September 11, 2012, 12:00 – 1:30 p.m. CT
Each year, the organizers of the IPO Annual Meeting invite one CEO to deliver a keynote luncheon address. This year, Mr. Warma has been selected to provide insight on the role of intellectual property rights from the perspective of business.
The 8th Annual Burrill Personalized Medicine Meeting
This meeting of researchers, drug developers, analysts, investors and other life science industry representatives will take place September 13-14, 2012 at the Bentley Reserve & Conference Center in San Francisco.
“Personalized Medicine From a Drug Developer’s Point of View”
Panel participation by Mr. Warma
Friday, September 14, 2012, 9:30 – 10:30 a.m. PT
Mr. Warma will join several additional panelists as they discuss the implications that advances in personalized medicine are having on the drug development business. Mr. Warma will share Opexa’s experiences regarding the clinical development of Tcelna, the first ever personalized T-cell therapy for MS patients.